Himadri Speciality Chemical Ltd Approves Major Capex for CNT, SSCB Manufacturing Amidst Strong Q1 Performance

Himadri Speciality Chemical Ltd Approves Major Capex for CNT, SSCB Manufacturing Amidst Strong Q1 Performance​

Himadri Speciality Chemical Ltd (HSCL) announced significant strategic capacity expansion plans following its Board meeting held on July 15, 2026. The Board approved several substantial investments focused on advanced materials, including Carbon Nano Tubes (CNT) and Super Speciality Carbon Black (SSCB), while also approving a major capacity enhancement for Anthraquinone and Carbazole production.

The company released the Unaudited Financial Results (Consolidated and Standalone) for the quarter ending June 30, 2026, alongside details of these strategic investments.

Q1 FY26 Financial Overview​

The consolidated financial performance reflected strong operational metrics in the first quarter of fiscal year 2026.


In terms of segment performance, the Carbon materials and chemicals segment reported consolidated revenue of 1,278.90 in the quarter ended June 30, 2026, compared to 1,112.85 in the corresponding period of the previous year. The Total Revenue from Operations for this segment stood at 1,431.88 in the current quarter.

Strategic Investments Drive Future Growth​

The Board approved three key capital expenditure (Capex) projects designed to position the company in high-growth advanced materials markets and reduce import dependency. These investments are slated to be funded primarily through internal accruals.

Carbon Nano Tubes (CNT) Facility:
A Capex of Rs 70 Crores was approved for setting up India's First CNT manufacturing facility in West Bengal using in-house developed technology. This facility aims to achieve an annual production capacity of 200 MT and is expected to be commissioned by Q4FY27.

Super Speciality Carbon Black (SSCB):
The company also approved a Capex of Rs 170 Crores for manufacturing Super Speciality Carbon Black with a planned capacity of 6,000 MTPA. This project will be implemented at the existing carbon black facility and is expected to be commissioned by Q4FY28.

Anthraquinone and Carbazole Expansion:
In addition to an earlier approval of Rs 120 Crores for setting up a specialty product manufacturing facility (which was initially planned for 2600 MTPA), the Board approved an additional Capex of Rs 128 Crores. This investment is intended to scale the capacity of Anthraquinone and Carbazole production from 2600 MTPA to 5300 MTPA.

The expansion project is structured in two phases:

• Phase 1: Targeting a 2600 MTPA capacity, scheduled for commissioning by Q2FY27.
• Phase 2: Focusing on the remaining 2700 MTPA capacity, expected to be commissioned by Q2FY28.

Market Positioning and Outlook​

The strategic investments are set to significantly strengthen Himadri's position in niche global markets. The newly approved CNT facility is intended to provide access to high-growth sectors such as EVs, semiconductors, and energy storage. Similarly, the SSCB line is expected to deliver higher value realization across applications like Engineering plastics and conductive applications.

CNT, which forms part of the Advanced Materials/Nanomaterials industry, is highly sought after in industries including electric vehicles (EVs), electronics, composites for aerospace and automotive, and energy storage solutions such as batteries and supercapacitors.

HSCL Stock Price Movement​

Today, shares of Himadri Speciality Chemical Limited climbed to close at ₹680.4 after gaining 1.34% in trading. The stock delivered this performance amid heavy activity, handling over 6.53 million shares of volume during the session.